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Colorectal cancer remains as one of the most common cancers worldwide.2
Although screening can reduce cancer-related mortality, only a modest decrease in
mortality has been achieved by conventional screening program. Furthermore,
only less than 50% of the population has been appropriately screened. The
availability of an accurate, non-invasive, cost-effective screening tool might
increase the number of participants in screening program who are reluctant to
undergo more invasive tests. Most of sporadic colorectal cancers develop as the
result of progressive accumulation of genetic and epigenetic alterations that lead to
the transformation of normal colonic epithelium to colon adenocarcinoma.3 Given
the fact that epithelial cells of the colon including tumor cells are continually
exfoliated and mixed into stool,4 genomic DNA can be isolated from these tumor
cells, and alterations of DNA in colon polyps and cancer can be analyzed.
(Epi)mutational profiles of each tumor cell in tumorigenesis are highly variable,
therefore, identification of a specific panel of genes that are altered in the vast
majority of precancerous and cancer cells is critical to increase the test sensitivity.
Several types of alterations, including genetic and epigenetic, of genomic DNA in
stool of colorectal cancer patients have been evaluated for potential use as
biomarkers for cancer screening. 
What is stool DNA testing?
To avoid misconception hereby, we define stool DNA test as a DNA-based
diagnostic test for colorectal cancer whereas genetic testing as an analysis of germ-
line DNA from blood lymphocytes to define a hereditary condition such as
familial adenomatous polyposis or Lynch syndrome. 
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Colorectal cancer (CRC) is one of the most common malignancies and leading cause of cancer-related deaths in the
world.1 However, it may be treated effectively by surgical removal of the cancerous tissue if detected at early stages.
Conventional tools for screening CRC are either invasive or inaccurate. Therefore, there is an urgent need to develop
a reliable screening tools for CRC to significantly reduce its morbidity. In this regard, a novel DNA markers-based
detection in stool is emerging as a promising approach.
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Point mutations of genes 
Point mutations of following three genes that are often
implicated in CRC have been targeted for stool DNA mar-
kers: 1) Adenomatous polyopsis coli (APC) residing on chro-
mosome 5q, tumor suppressor gene. Multiple point mutations
occur early in the development of an adenoma. 2) K-ras,
found on chromosome 12, oncogene. Multiple point muta-
tions of this gene frequently appear during CRC develop-
ment following APC mutations. 3) TP53, tumor suppressor
gene, located on chromosome 17p. Mutations at this gene
are often found later in cancer progression and associated
with larger adenoma with more severe grade of dysplasia. 
Microsatellite instability (MI)
As consequence of mutations of mismatch repair gene
products, microsatellites and repeating sequences of DNA
become instable. One of microsatellites, BAT-26 which is
single locus of 26 consecutive adenine nucleotides, is
associated with loss of function of a mismatch gene. Thus,
alteration in microsatellite on the BAT-26 locus has often
been used as a maker in stool DNA test.1
Long -fragment human DNA: DNA integrity 
Normally, genomic DNA is fragmented into short length
(< 200 bp) by endonucleases during apoptosis. Longer frag-
ment human DNAs (larger than 200 bp) exist more abun-
dantly in stool-derived DNA samples because neoplastic
cells resistant to apoptosis are exfoliated into colonic lumen.
This observation suggests that DNA integrity may be used
as a marker for stool DNA test.5-7
Evaluation of multi-target genetic markers for stool
DNA test
Small scale pilot study for testing multitarget genetic markers
in stool for early detection of colorectal neoplasia includes
21 mutations in APC, K-Ras and p53 as well as BAT-26
and DNA Integrity Assay (DIA) which was developed by
Exact Sciences and marketed as Pre-GenPlus (version I) by
Lab Corp. These approaches detected adenocarcinoma and
adenoma with sensitivity ranging from 62% to 91% and
from 27% to 82%, respectively. Specificity was high, ranging
from 93% to 98%, for subjects without colorectal neopla-
sia.7 However, in the most prominent large scale prospective
screening trial, the same markers as used in version I test
had a lower sensitivity of 52% for invasive and 18% for
advanced cancer, although the specificity of this particular
assay was 94%.8 This lower sensitivity was attributed to
unexpected low rate of positivity for DIA. Later, however,
it was known that the suboptimal performance of DIA was
due to DNA degradation during specimen mailing to the
lab. Indeed, better sensitivity of this marker was achieved
with improved condition of sample preparation.9 According
to Song et al. who estimated clinical and economic conse-
quences of fecal DNA testing and compared them with
conventional CRC screening using Markov model, the
sensitivity of the panel of DNA markers in detecting
adenocarcinoma and adenoma in stool needs to be increased
to 65% and 40%, respectively.12 In order for DNA testing in
stool to be cost effective, the cost per test needs to be adjusted
to $195. Experimental strategies that have improved analy-
tical sensitivity of PCR to detect very low number of copies
of tumor DNA in stool enhanced the performance of fecal
DNA testing further. BEAMing technology identified DNA
mutations in stool (92%; 23 of 25 stool DNA from CRC
patients) and a digital melt curve (DMC) assay showed a
high level of sensitivity in detecting individuals with colorec-
tal neoplasms (90%; 28 of 31 tumors) and better perfor-
mance in detecting those with advanced adenoma (59%; 16
of 27 advanced adenoma).10,11 In these studies, however,
they did not comment on the specificity. As a general rule,
sensitivity is increased at the expense of clinical specificity.
Thus, additional refinements that maximize sensitivity and
specificity for both advanced adenomas and cancer are
necessary before widespread clinical implementation.
Epigenetic alterations
Aberrant DNA methylation is a major epigenetic change
that is early and common event in human tumorigenesis.13-16
Methylation at a specific cytosine residue of CpG site is a
key component of the epigenetic mechanism that is asso-
ciated with changes in gene expression without change of
DNA sequence in tumorigenesis. In CRC, several genes
have been identified that are aberrantly hypermethylated
while not in normal mucosa. There have been several
attempts to utilize such tumor-associated DNA methylation
as a biomarker for potential early detection of colon cancer. 
Candidate gene approach to methylation markers for
stool DNA test 
Epigenetic studies have focused on analyzing single gene
methylation as a candidate for a potential biomarker for
stool DNA-based screening of CRC. Muller et al.17 assessed
stool DNA for SFRP2 methylation from three independent
sets of patients with CRC with sensitivity of 77% to 90%
and a specificity of 77%.Three different groups also reported
comparable data for SFRP2 methylation in stool DNA, with
a sensitivity of 87% to 94% and a specificity of 85% to
90%.18-20 Other single methylation marker assessment such
as SFRP1 gene for methylation status in stool reported a
sensitivity of 89% and specificity of 86% in stool samples
from 36 patients with colorectal neoplasia (7 adenoma, 29
colorectal cancer) and 17 healthy control subjects.21 Chen et
al. found that vimentin gene is transcriptionally inactive in
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normal colon epithelial cells with very low level of methy-
lation on CpG region upstream of the first exon and continu-
ing across the first two-thirds of the first exon. This region
becomes highly methylated in primary tumor of colon
cancer. They detected aberrant hypermethylation in 83%
(38 of 46) and 53% (57 of 107) of primary tumor tissues
from two independent groups of colon cancer. However, in
its recapitulation test in stool-derived DNA, they detected
only 46% from third set of 94 colon cancer patients versus
10% from normal colonoscopy.22 Itzkowitz and colleagues9
further validated vimentin methylation as a marker for
cancer detection in stool DNA under better condition of
DNA preparation and obtained a remarkably improved
sensitivity of 72.5% (29 of 40 patients) and a specificity of
86.9% (16 of 122 normal individuals).
Combination of vimentin methylation test plus DNA
Integrity Assay (DIA)
Imperiale et al.8 analysed the performance of combination
markers for stool DNA test, namely as second generation
assay, using the same markers of version I used in the pre-
vious multicenter study plus vimentin methylation as a
marker. They improved the way of sample collection with
new DNA stabilization buffer which was developed for
preventing DNA degradation23 and gene-based DNA capture
to enhance DNA extraction from stool.23,24 Stool samples
from 40 patients with CRC and 122 subjects with normal
colonoscopy were used for analysis. The sensitivity of the
version I markers increased from 51.6% to 72.5% due to
improved performance of DIA from 3.2% to 65%. Aberrant
methylation of vimentin gene alone provided high values of
sensitivity and specificity of 72.5% and 89.9%, respec-
tively, that are very similar to those of panel of version I
markers. The least complex assay, using combination of
only two markers consisting of vimentin and the best mar-
ker of DIA components, yielded a maximum sensitivity of
87.5% and specificity of 82%. DNA integrity as a biomarker
for CRC screening remains to be determined. It has been
known that the stability of long-length genomic DNA is not
constantly maintained during colon transit and fecal storage.
Indeed, long-length DNAs are detected more frequently in
left-side cancer than right-side one. Furthermore, long
length DNA may not be specific for neoplasia of CRC,
because its presence could be attributed to increased inflam-
mation or field cancerlization characterized by enhanced
proliferation and apoptosis resistance.7,25 Notably, single
marker test for vimentin methylation has replaced 23 mar-
kers test which had previously been developed by Exact-
Sciences and is currently the only commercially available
stool DNA test through Lab Corp in the name of ColoSureTM
($240 per test), although the performance of vimentin
methylation in detection of advanced adenomas has not yet
been defined.9
Genome-wide approach in identification of novel 
methylation markers
Glockner et al.26 reported recently that hypermethylation of
tissue factor pathway inhibitor 2 (TFPI2) gene in stool
could be utilized as a marker for CRC screening. As a fre-
quently methylated gene in human CRC, they used gene
expression microarray-based strategy to identify the methy-
lation of TFPI2 gene. This gene was reactivated in their
microarray analysis by methylation inhibiting agent, DAC,
and was frequently found to be methylated in colon cancer
cell lines. Many previous studies showed aberrant methy-
lation of TFPI2 gene in various cancers.27-32 They detected
aberrant methylation of this gene by methylation specific
PCR in 94% of invasive errated adenoma (16 of 17), 100%
of tubular adenomas (17 of 17), and 100% of vilous adeno-
mas (22 of 22), all of which represent preinvasive stages,
and in 99% of invasive colorectal cancer states I to IV (114
out of 115), almost all colorectal adenoma. They observed
TFPI2 methylation in stool DNA from stage I to III CRC
patients with a sensitivity of 76% to 89% and a specificity
of 79% to 93%. However, for adenoma, although more than
95% sensitivity was detected in primary tumor tissues, only
21% to 43% sensitivity was achieved for stool DNA samples,
indicating that fewer cells are shed by adenomas.
Detection of DNA molecular markers in stool is an exciting
new technology that shows increasing promise as a way to
screen colorectal cancer. Detecting premalignant adenoma
is the key target of any approach of screenings which aim at
preventing colorectal cancer. In this point, stool DNA testing
with molecular markers has shown to be superior to fecal
occult blood testing for adenoma detection. However, given
clinical and economical consequence compared with colo-
noscopy, additional refinements of panel of biomarkers that
maximize sensitivity and specificity for both advanced
adenomas and cancer and cost-effectiveness are necessary.
There are many new approaches in the development of high-
performance molecular markers that are ideal screening
tools which are sensitive, specific, cost-effective, and user
friendly for clinical implementation. Individuals with a
positive stool DNA test are referred for colonoscopy. Ulti-
mately, introduction of new stool-based DNA test with a
panel of molecular markers is expected to encourage parti-
cipation in screening program of colorectal cancer.
This study was supported by a grant (Project No. 0405-BC01-
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